Lipid Genomics Products
The mission at Lipid Genomics is to use a personalized medicine approach to develop diagnostics and therapeutics for patients with genetic cholesterol disorders.


As such, we have developed three product lines:


  • FDA allowed phase 1 clinical trial to evaluate the safety and efficacy of a repurposed small molecule in patients who are or are not carriers of certain genetic variants within the HDL cholesterol receptor, SCARB1.


  • Recombinant human biologic for immune checkpoint inhibitor, lymphocyte activation gene-3.


  • Diagnostic assay for lymphocyte activation gene-3 as a biomarker for dysfunctional HDL and other chronic inflammatory diseases.